FORV/S

Margin Transformation: Identification & Implementation of Best Value Opportunities

February 16, 2023

Kentucky HFMA 2023 Annual Conference

Agenda

- Meet the Panel
- Why Margin Improvement
- Methodology & Opportunities
- Case Examples
- Q & A



FORV/S

Meet the Panelist



Chris Woosley
Moderator
Partner
FORVIS



Dan Clark
Managing Director
Revenue Cycle
FORVIS



Beth McCraw, DNP, APRN, ACNS-BC
Vice President of Nursing & Clinical Services
Chief Nursing Officer
Jennie Stuart Health



Brian Bell
Managing Director
Pharmacy & Clinic Conversion



Kevin Rash
Director
Operations & Expense Management
FORVIS



Jennie Stuart Healthcare

- Hopkinsville, KY
- Acute-care hospital licensed for 123 beds
- Private, not-for-profit community hospital
- Serving patients for over 100 years
- \$560 million total patient revenue
- Rural Sole Community Hospital
- Primary service areas
 - Christian, Trigg and Todd counties
- Secondary service areas
 - Caldwell, Hopkins, Muhlenberg and Montgomery (TN) counties











Question #1

Of organizations experiencing financial strain, do you see the disruption primary cause to be related:

- A Provider Relief Funding Evaporation
- B Staffing Challenges post Pandemic/Rebased Wages
- C Shifting Consumer Utilization/Market Volumes Post Pandemic
- **D** Other



Why Margin Improvement?




- Post-pandemic headwinds for healthcare executives:
 - Supply costs at all time high
 - Revenue cycle metrics off track
 - Labor shortages, contractors, and employee benefit rates unprecedented
 - Inflation driving increases in non-supply areas (e.g., Utilities)
 - Remote workforce
 - CARES act funding suspended
 - "The right" volumes sluggish to return





National Margin Results

More than a third of hospitals posted negative operating margins during 2021 and most US hospitals reported significantly greater margin declines in Q1 2022





^{*} Comprised of national median of results adjusted for allocations to hospitals from corporate, physician and other entities. National Hospital Flashreport, May 2022 KH

Short and long-term challenges remain

FOUR CHALLENGES



Manage capacity, staff resiliency through remaining Covid-19 surges



Stabilize financials. recover volume



Adjust to new consumer behaviors, preferences



Address changing health status, equity

NEAR TERM

LONGER TERM



FORV/S

Methodology & Areas of Focus



Proven Methodology



Opportunity Assessment



Data gathering and analysis

including performance benchmarking, data analysis, policy review, and organizational structure evaluation, and reporting assessment



Targeted interviews

with management
and staff in key
functional areas across the
revenue cycle to review
current-state workflows



Report-out and prioritization

of top improvement areas and financial impacts that include cash acceleration opportunities, quick wins, and long-term work efforts



Question #2

On the topic of Revenue Cycle, where do you see the greatest area of revenue risk or financial opportunity within your organization?

- A Increasing Denials
- B Vendor Management & outsourced services
- C Patient Liability
- **D** Payer pressure to adjust/down code services



Opportunities within a Margin Improvement Plan



Integrity **Patient** Liability

& Revenue

Revenue Cycle

Denials Management

System **Optimization**

Vendor Management

Charge Capture

Pricing Strategy

Status **Determination**

KPI Monitoring

Payor Strategies & **Solutions**

> Cost Reporting

DSH, DRG & UC

Medicare Bad Debt

Managed Care Strategy

Reimbursement 340B

Provider **Based Clinics**

Pharmacy



Population-**Based Models**

Medicare atrisk Modeling

Compensation Plan

Physician Office Performance Optimization



Organizational **KPIs**

Organizational Structure

Span of Control

Departmental Efficiency Benchmarking and Monitoring

Premium Pay Code Alignment

Contract Staff Cost & Utilization



Expense Benchmarking

> **GPO** Performance

Purchased Services

Benefit Plan

Expense Management Physician Preference Items

Utilities

NonLabor MedSurg **Supplies**

Pharmacy

Technology

Support Services



Question #3

When considering pharmacy and 340B performance for the upcoming year, what is your top priority to expand 340B and improve pharmacy spending?


- A Convert clinics from physician offices to provider-based clinics
- B Open an entity-owned retail pharmacy
- **C** Expand contract pharmacy arrangements and/or start submitting data to 340B ESP
- **D** Assess non-340B spending and develop strategy to change prescribing and drug utilization



Case Example - Provider-Based Clinics and 340B

Jennie Stuart Health: Jennie Stuart Health (JSH) desired to optimize their reimbursement for their clinics and increase 340B savings. The increase in reimbursement and savings will allow them to expand their services they provide to their patients and community. Leadership desired assistance with assessing and implementation of provider-based clinics and expanding their 340B program. FORVIS is serving as trusted advisors with proven experience and expertise.

FORVIS was engaged to assess clinic conversion opportunities, assist with implementation of clinics, submitting provider-based clinic packages to CMS and serving as 340B resource for 340B and pharmacy expansion.





Question #4


When considering service line performance with a goal of excellence, where would you want to focus the efforts of assessment?

- A Governance/Management
- B Patient, Provider & Employee Phases of Care
- C Market Capture, Leakage, & Community Needs
- **D** Operational Performance for Expense Management & Revenue Enhancement



Case Example – Surgery Service Line

Jennie Stuart Health: Jennie Stuart Health desired to optimize their surgical services to a level of Surgery Excellence, to include financial improvement, operational efficiencies, and re-alignment to market and consumer needs/demands.



Key Initiatives:

- Market shift in key service lines
- Access and Utilization of surgery resources
- Coding and Billing of surgical services
- Cost of physician preference items & clinical variance
- Measuring & Monitoring Key Performance Indicators
- Revenue Cycle opportunities denials & collections

FORV/S

Q & A Time

- Chris Woosley: <u>Chris.Woosley@forvis.com</u>
- > Beth McCraw: bethmccraw@jsmc.org
- Kevin Rash: <u>Kevin.Rash@forvis.com</u>
- > Brian Bell: Brian.Bell@forvis.com
- Dan Clark: <u>Dan.Clark@forvis.com</u>

forvis.com

The information set forth in this presentation contains the analysis and conclusions of the author(s) based upon his/her/their research and analysis of industry information and legal authorities. Such analysis and conclusions should not be deemed opinions or conclusions by FORVIS or the author(s) as to any individual situation as situations are fact specific. The reader should perform its own analysis and form its own conclusions regarding any specific situation. Further, the author(s) conclusions may be revised without notice with or without changes in industry information and legal authorities.

FORVIS has been registered in the U.S. Patent and Trademark Office, which registration is pending.



Thank You!

forvis.com

The information set forth in this presentation contains the analysis and conclusions of the author(s) based upon his/her/their research and analysis of industry information and legal authorities. Such analysis and conclusions should not be deemed opinions or conclusions by FORVIS or the author(s) as to any individual situation as situations are fact specific. The reader should perform its own analysis and form its own conclusions regarding any specific situation. Further, the author(s) conclusions may be revised without notice with or without changes in industry information and legal authorities.

FORVIS has been registered in the U.S. Patent and Trademark Office, which registration is pending.



Appendix: About FORVIS

forvis.com

The information set forth in this presentation contains the analysis and conclusions of the author(s) based upon his/her/their research and analysis of industry information and legal authorities. Such analysis and conclusions should not be deemed opinions or conclusions by FORVIS or the author(s) as to any individual situation as situations are fact specific. The reader should perform its own analysis and form its own conclusions regarding any specific situation. Further, the author(s) conclusions may be revised without notice with or without changes in industry information and legal authorities.

FORVIS has been registered in the U.S. Patent and Trademark Office, which registration is pending.



BKD + DHG = FORV/S

Effective June 1, 2022



\$1.4BN

in revenue

8th

largest US firm

530+

partners & principals

5,400+

team members

69

markets

27

states + UK & Caymans



Healthcare Industry Footprint

Market
Familiarity
+
Backyard
Proximity

DHG~2100
Healthcare Clients

COMBINED
~6100
Healthcare Clients

\$250M | 950+ | 175+ team members | PPDMDs

Access
Hospitals

FORVIS Healthcare

Modern Healthcare $2021 \\ \label{eq:constraint}$ by the numbers

#10 BKD CPAs & Advisors

Largest Management Consulting Firms

Consulting
Top 50
Healthcare Consultants

of 2021

10 MOST TRUSTED
HEALTHCARI
CONSULTING
COMPANIES TO THE

~950

Total Healthcare Personnel

175
PPDMDs

465

Consultants,
Including 180 Reimbursement
Members

320

Audit

49

Tax

FORV/S